Skip to content
Home
Technology
The platform
Artificial Intelligence
BioClick
Nobel Prize heritage
Biosolution phases
Scientific papers
Patents
Pipeline
Pipeline overview
NCT: Over-the-Counter
NCT: Pharma
Cannabinoids
Santalene
Become a partner
Investors
Stock information
News
Email signup
Investor Relation Contacts
Governance
SEC Filings
Video
About
Leadership team
History
Jobs
Policies
Terms of Use
FCOI
Privacy Policy
Contact
News
Latest news
Media coverage
Investor news
News archive
Homepage
Open navigation
Home
Technology
The platform
Artificial Intelligence
BioClick
Nobel Prize heritage
Biosolution phases
Scientific papers
Patents
Pipeline
Pipeline overview
NCT: Over-the-Counter
NCT: Pharma
Cannabinoids
Santalene
Become a partner
Investors
Stock information
News
Email signup
Investor Relation Contacts
Governance
SEC Filings
Video
About
Leadership team
History
Jobs
Policies
Terms of Use
FCOI
Privacy Policy
Contact
News
Latest news
Media coverage
Investor news
News archive
investor
nutraceuticals
medicine
EXOZ investor update: eXoZymes de-risks scale-up with Cayman Chemical, validating tech transfer with pharma-grade output
March 18, 2026
press release
nutraceuticals
medicine
video
Video interview: Successful pilot scale run with Cayman Chemical validates eXoZymes' technology and scalability
March 18, 2026
press release
nutraceuticals
medicine
eXoZymes’ CCO Damien Perriman to Present a NCT solution at next week’s MISTA Symposium
March 12, 2026
investor
press clippings
video
The Big Skinny: Lou Basenese states that eXoZymes is the BASF of 2026
February 16, 2026
press release
investor
With refreshed brand eXoZymes sharpens pharmaceutical focus to drive platform leverage and long-term value creation
February 10, 2026
heltzen
investor
press clippings
video
Nasdaq: Michael B. Spector interviews CEO Heltzen
February 5, 2026
investor
press clippings
yahoo! finance: eXoZymes demonstrates end-to-end biomanufacturability of NCT, from reaction to high-purity isolated product
January 30, 2026
press release
investor
nutraceuticals
science
eXoZymes advancing commercial readiness with profound production metrics on initial NCT pilot run
January 29, 2026
investor
press clippings
video
Beryl Elites: Interview with Capital Markets Advisor, Sanjeev Srivastava
January 8, 2026
heltzen
investor
press clippings
video
Beryl Elites: What is Artificial Evolution - an interview with CEO Heltzen
January 7, 2026
Previous page
Page 1 of 11
Next page